VLViviana P. Lutzky

Viviana P. Lutzky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Viviana P. Lutzky has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-Invasive Distal Airway Proteomics by Particles in Exhaled Air (PExA) Sampling Demonstrates Shared Proteomic Features with Matched Bronchoalveolar Lavage

    by Kiara M. Knuckey, Sjane Timmins, Amy Pham, Maxine E. Tan, Penny L. Groves, Viviana P. Lutzky, Subash K. Rai, Alan M. Carew, Daniel C. Chambers, Simon H. Apte

    Repeated molecular sampling of the distal airways is constrained by the invasive nature of bronchoalveolar lavage (BAL), limiting its use in healthy control populations, longitudinal studies, clinical trials and occupational screening. Particles in exhaled air (PExA) sampling offers a non-invasive approach to distal-airway sampling, although whether it captures the same proteins and relative protein abundance as BAL has not been established. We performed the first proof-of-principle high-dimensional proteomic comparison of matched BAL and PExA samples collected from three individuals with silicosis using the SomaScan 11K platform. Within individuals, PExA and BAL shared a substantial subset of detectable proteins and showed similar cross-protein signal patterns, with Pearson correlation coefficients ranging from 0.48 to 0.71. Analytes recurrently detected across all three PExA samples were strongly enriched among those consistently detected in BAL and included pulmonary surfactant proteins and mediators associated with epithelial injury, alveolar macrophage function, inflammation and fibrosis. The PExA findings also showed substantial overlap with an independent published PExA-only proteomic dataset. These proof-of-principle findings show that non-invasive PExA sampling can capture a biologically meaningful subset of the matched BAL proteome. PExA may therefore offer a practical approach for repeated molecular profiling of the distal airways and warrants further evaluation for respiratory biomarker discovery and disease monitoring.

  • Open Access

    Clinical Evaluation of Long-Read Sequencing for Telomere Length Assessment in Human Blood and Lung Tissues

    by Viviana P. Lutzky, Subash K. Rai, Maxine E. Tan, Penny L. Groves, Kiara M. Knuckey, John A. Mackintosh, Mathew J. K. Jones, Simon H. Apte, Daniel C. Chambers

    Telomere length (TL) measurement is increasingly used in the evaluation of pulmonary fibrosis and suspected telomere biology disorders, with flow cytometry–fluorescence in situ hybridisation (Flow-FISH) representing the current clinical reference standard. However, Flow-FISH provides a population-averaged relative TL, has a high analytical variability and is largely restricted to PBMC-based measurements. We evaluated a long-read sequencing–based assay, Telo-Seq, for clinical TL assessment in an Australian cohort. In this observational study, TL was measured by both Flow-FISH and Telo-Seq in PBMC from 156 healthy controls and a small cohort of 24 patients undergoing clinical evaluation for interstitial lung disease, using the same blood processing and assay workflows. In an exploratory subset of samples, TL was also assessed in whole lung lavage fluid and explanted lung tissue. In the assessment of PBMC, Telo-Seq correlated with Flow-FISH (R2 ≈ 0.77) and showed lower inter-assay variability (CV ~1.4% vs. ~4.6%). Classification relative to assay-specific age-adjusted 10th-percentile thresholds was largely concordant between Flow-FISH and Telo-Seq, although discordant cases occurred in both directions near clinically relevant thresholds. Long-read sequencing provides a reproducible approach to TL assessment and supports further evaluation in disease-relevant tissues.

  • Open Access

    Alveolar Lipid–Macrophage Networks at the Intersection of Pulmonary Fibrosis

    by Simon H. Apte, Viviana P. Lutzky, Penny L. Groves, Daniel C. Chambers

    Idiopathic pulmonary fibrosis (IPF) is characterised by progressive parenchymal remodelling, driven by epithelial dysfunction, fibroblast activation, and altered immune regulation within the distal lung. Alveolar macrophages (AMs) reside in a surfactant-rich environment and are specialised for continuous lipid handling, yet the significance of this metabolic role for macrophage heterogeneity and fibrotic progression has remained incompletely integrated across studies. In this review, we synthesise evidence from human lung tissue, experimental models, lipidomic analyses, and clinical investigations to place macrophage populations described in IPF—including FABP4-high homeostatic cells and SPP1-associated disease-enriched states—within a unified lipid-metabolic context. We show that macrophage heterogeneity in IPF can be understood as a variation within a core lipid-handling programme rather than the emergence of distinct macrophage lineages. Profibrotic macrophage states are characterised by altered lipid processing and signalling, including dysregulated sterol handling, lysophospholipid pathways, and eicosanoid balance, which impair surfactant turnover and contribute to fibroblast activation. Importantly, experimental and clinical data indicate that macrophage lipid-metabolic programmes remain modifiable, although definitive disease-modifying efficacy in IPF has yet to be established. Framing macrophage states within a lipid-metabolic framework provides a coherent basis for interpreting heterogeneous datasets and supports the rationale for therapeutic strategies aimed at stabilising or restoring macrophage lipid handling in fibrotic lung disease.


  • Open Access

    Proteome-Wide Serological Profiling Reveals Broad Elevation of EBV Immunity in Idiopathic Pulmonary Fibrosis

    by Yomani D. Sarathkumara, Kiara M. Knuckey, Viviana P. Lutzky, Penny L. Groves, Maxine E. Tan, Daniel C. Chambers, Carla Proietti, Denise L. Doolan, Simon H. Apte

    Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with uncertain etiology. Chronic viral infection, including Epstein–Barr virus (EBV), has been implicated as a potential driver of repetitive epithelial injury and dysregulated repair. We sought to evaluate and define the breadth versus specificity of EBV-directed humoral immunity in IPF. We performed proteome-scale serological profiling using an EBV protein microarray (202 proteins) representing all proteins expressed by the EBV proteome (type I and II) on plasma samples from 32 patients with confirmed IPF (87.5% male; mean age 60.9 years) and 15 healthy disease-free controls (40% male; mean age 57.9 years). Per-sample global EBV IgG means were higher in IPF than controls (Welch p = 0.005), and the difference persisted after sex adjustment (p = 0.012). Although no single antigen met a stringent FDR significance threshold, 10 EBV antigen-specific antibody responses showed nominal elevation in IPF, with 2 remaining nominally significant after sex adjustment and 5 additional antibody responses reaching significance only in linear regression models. Overall, these results support the concept that IPF is associated with a diffuse elevation of EBV-directed humoral responses rather than antigen-specific dominance, consistent with ongoing, low-level viral reactivation. The presence of an EBV-negative subgroup within the IPF cohort underscores etiological heterogeneity within IPF.

  • Open Access

    Transcriptomic Plasticity of Human Alveolar Macrophages Revealed by Single-Cell RNA Sequencing Following Drug Exposure: Implications for Therapeutic Development

    by Penny L. Groves, Levi Hockey, Brendan J. O’sullivan, Lai-Ying Zhang, Zherui Xiong, Quan H. Nguyen, Maxine E. Tan, Viviana P. Lutzky, Rohan A. Davis, Daniel C. Chambers, et al.

    Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.


  • Open Access

    Transcriptomic Plasticity of Human Alveolar Macrophages Revealed by Single-Cell RNA Sequencing Following Drug Exposure: Implications for Therapeutic Development

    by Penny L Groves, Levi Hockey, Brendan J O'Sullivan, Lai-Ying Zhang, Zherui Xiong, Quan H Nguyen, Maxine E Tan, Viviana P Lutzky, Rohan A Davis, Daniel C Chambers, et al.

    Alveolar macrophages (AM) must perform three seemingly opposing roles including homeostasis, driving inflammation, and facilitating tissue repair. Whilst there is now consensus (supported by a large body of human single cell RNA sequencing (scRNA-seq) data) that the cell subsets that perform these tasks can readily be found based on their transcriptome, their ontogeny has remained unclear. Moreover, there is agreement that in all types of pulmonary fibrosis (PF) there is an expanded population of profibrotic AM that may aberrantly drive PF. From a therapeutic viewpoint, there is great appeal in the notion that the transcriptional program in different AM subsets is not fixed but remains plastic and amenable to pharmacological reprogramming. Accordingly, this study addresses this question by performing scRNA-seq on human AM following treatment with drugs or perturbagens including pioglitazone, trametinib, nintedanib, lipopolysaccharide and the natural compound endiandrin A. Each treatment induced a unique global transcriptional change, driving the cells towards distinct subsets, further supported by trajectory analysis, confirming a high level of plasticity. Confirmatory experiments using qPCR demonstrated that single exposure to a compound induced a relatively stable transcriptome, whereas serial exposure to a different compound allowed the cells to be reprogrammed yet again to a different phenotype. These findings add new insight into the biology of AM and support the development of novel therapies to treat PF.


  • Open Access

    A Methodological Approach to Identify Natural Compounds with Antifibrotic Activity and the Potential to Treat Pulmonary Fibrosis Using Single-Cell Sequencing and Primary Human Lung Macrophages

    by Simon H. Apte, Penny L. Groves, Maxine E. Tan, Viviana P. Lutzky, Tharushi de Silva, Joshua N. Monteith, Stephanie T. Yerkovich, Brendan J. O’sullivan, Rohan A. Davis, Daniel C. Chambers

    Idiopathic pulmonary fibrosis (IPF) is the most common and lethal form of the interstitial pneumonias. The cause of the disease is unknown, and new therapies that stop or reverse disease progression are desperately needed. Recent advances in next-generation sequencing have led to an abundance of freely available, clinically relevant, organ-and-disease-specific, single-cell transcriptomic data, including studies from patients with IPF. We mined data from published IPF data sets and identified gene signatures delineating pro-fibrotic or antifibrotic macrophages and then used the Enrichr platform to identify compounds with the potential to drive the macrophages toward the antifibrotic transcriptotype. We then began testing these compounds in a novel in vitro phenotypic drug screening assay utilising human lung macrophages recovered from whole-lung lavage of patients with silicosis. As predicted by the Enrichr tool, glitazones potently modulated macrophage gene expression towards the antifibrotic phenotype. Next, we assayed a subset of the NatureBank pure compound library and identified the cyclobutane lignan, endiandrin A, which was isolated from the roots of the endemic Australian rainforest plant, Endiandra anthropophagorum, with a similar antifibrotic potential to the glitazones. These methods open new avenues of exploration to find treatments for lung fibrosis.